Search Results

Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, announced that management will participate in the following upcoming investor conferences.

Tempest Therapeutics, Inc. announced new positive data from the ongoing global randomized Phase 1b/2 clinical study in which amezalpat2, Tempest’s PPAR⍺ antagonist, delivered a six-month improvement in median overall survival advantage when combined with atezolizumab and bevacizumab in a comparison to atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.

Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, reported financial results for the quarter ended March 31, 2024, and provided a corporate update.

Tempest Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 14,000 shares of its common stock under the Company’s 2023 Inducement Plan.

Tempest Therapeutics, Inc. announced the company plans to report new data from the global randomized Phase 1b/2 combination study of amezalpat with atezolizumab and bevacizumab in first-line treatment of hepatocellular carcinoma in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m. ET.

Tempest Therapeutics, Inc. announced that Stephen Brady, president and chief executive officer of Tempest, will present at the 44th Annual TD Cowen Healthcare Conference on Monday, March 4, 2024 at 9:10 a.m. ET.

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the year ended 2023 and provided a corporate update.

Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 5,400 shares of its common stock under the Company’s 2023 Inducement Plan.

Tempest Therapeutics, Inc. (Nasdaq: TPST) today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting demonstrating that TPST-1120 reduces kidney cancer (RCC) growth as a monotherapy, while also showing increased inhibition when combined with frontline chemotherapy and immunotherapy.